EA200100153A1 - Совместное назначение ингибиторов асат и ммр для лечения атеросклеротических поражений - Google Patents

Совместное назначение ингибиторов асат и ммр для лечения атеросклеротических поражений

Info

Publication number
EA200100153A1
EA200100153A1 EA200100153A EA200100153A EA200100153A1 EA 200100153 A1 EA200100153 A1 EA 200100153A1 EA 200100153 A EA200100153 A EA 200100153A EA 200100153 A EA200100153 A EA 200100153A EA 200100153 A1 EA200100153 A1 EA 200100153A1
Authority
EA
Eurasian Patent Office
Prior art keywords
asat
atherosclerotic
defects
treatment
mmp inhibitors
Prior art date
Application number
EA200100153A
Other languages
English (en)
Inventor
Томас Майкель Эндру Бокан
Original Assignee
Варнер-Ламберт Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Варнер-Ламберт Компани filed Critical Варнер-Ламберт Компани
Publication of EA200100153A1 publication Critical patent/EA200100153A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Предмет данного изобретения составляет совместное назначение веществ, ингибирующих АСАТ и ММР, для понижения компонентов атеросклеротического поражения, связанных с макрофагами и с клетками гладких мышц, которое приводит к ослаблению экспансии существующих поражений и развития новых поражений, предупреждает отрыв бляшек и способствует регрессии поражений у млекопитающих.Отчет о международном поиске был опубликован 2000.05.18.
EA200100153A 1998-07-21 1999-06-18 Совместное назначение ингибиторов асат и ммр для лечения атеросклеротических поражений EA200100153A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
EA200100153A1 true EA200100153A1 (ru) 2001-08-27

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100153A EA200100153A1 (ru) 1998-07-21 1999-06-18 Совместное назначение ингибиторов асат и ммр для лечения атеросклеротических поражений

Country Status (25)

Country Link
EP (1) EP1098662A2 (ru)
JP (1) JP2002521328A (ru)
KR (1) KR20010083134A (ru)
CN (1) CN1310629A (ru)
AP (1) AP2001002035A0 (ru)
AU (1) AU4701799A (ru)
BG (1) BG105162A (ru)
BR (1) BR9912296A (ru)
CA (1) CA2335062A1 (ru)
CZ (1) CZ2001126A3 (ru)
EA (1) EA200100153A1 (ru)
EE (1) EE200100046A (ru)
HR (1) HRP20010055A2 (ru)
HU (1) HUP0102880A3 (ru)
ID (1) ID30030A (ru)
IL (1) IL140982A0 (ru)
IS (1) IS5809A (ru)
NO (1) NO20010291L (ru)
OA (1) OA11584A (ru)
PL (1) PL346011A1 (ru)
SK (1) SK502001A3 (ru)
TR (1) TR200100205T2 (ru)
WO (1) WO2000004892A2 (ru)
YU (1) YU3501A (ru)
ZA (1) ZA200100294B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1414848A (zh) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Acat抑制剂对斑块破裂的预防
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
AU2001282541B2 (en) * 2000-09-01 2004-06-24 Sankyo Company, Limited Medicinal compositions
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
ATE399012T1 (de) * 2002-04-03 2008-07-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
JP4617449B2 (ja) * 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
WO2016113713A1 (en) * 2015-01-15 2016-07-21 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
NZ312571A (en) * 1995-08-04 2000-07-28 Warner Lambert Co Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein
DK0901466T3 (da) * 1996-05-17 2002-02-18 Warner Lambert Co Biphenylsulfonamid-matriksmetalloproteinase-inhibitorer
JP2000517341A (ja) * 1996-09-04 2000-12-26 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼ阻害剤およびそれらの治療的使用

Also Published As

Publication number Publication date
SK502001A3 (en) 2002-06-04
OA11584A (en) 2004-07-20
BR9912296A (pt) 2001-04-17
WO2000004892A3 (en) 2000-05-18
PL346011A1 (en) 2002-01-14
AU4701799A (en) 2000-02-14
NO20010291D0 (no) 2001-01-18
CA2335062A1 (en) 2000-02-03
YU3501A (sh) 2005-06-10
IL140982A0 (en) 2002-02-10
HRP20010055A2 (en) 2002-04-30
EE200100046A (et) 2002-06-17
IS5809A (is) 2001-01-12
EP1098662A2 (en) 2001-05-16
CN1310629A (zh) 2001-08-29
CZ2001126A3 (cs) 2002-01-16
ID30030A (id) 2001-11-01
HUP0102880A2 (en) 2002-06-29
AP2001002035A0 (en) 2001-03-31
WO2000004892A2 (en) 2000-02-03
TR200100205T2 (tr) 2001-05-21
HUP0102880A3 (en) 2002-11-28
ZA200100294B (en) 2002-01-10
JP2002521328A (ja) 2002-07-16
NO20010291L (no) 2001-01-18
BG105162A (en) 2001-12-29
KR20010083134A (ko) 2001-08-31

Similar Documents

Publication Publication Date Title
EA200100153A1 (ru) Совместное назначение ингибиторов асат и ммр для лечения атеросклеротических поражений
DE602004025030D1 (de) System für fussgelenksarthroplastie
DE1073432T1 (de) Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
ITBO990430A0 (it) Mezzo di fissazione femorale dei tendini di semitendinoso e del gracil e per la ricostruzione del legamento crociato anteriore .
EA199900384A1 (ru) Устройство для очистки межзубного промежутка и способ его изготовления
BR9813228A (pt) Formulação de 2-metil-tieno-benzodiazepina
NO975747D0 (no) Peptidylheterocykler for anvendelse ved behandling av trombin-relaterte mangler
DE69721554D1 (de) Wässrige reinigungs- und desinfektionsmittel mit niedrigem rückstand für harte oberflächen
DE29502880U1 (de) Endoskop für Ultraschallechographie
EA200000536A1 (ru) Применение комбинации ингибитора конвертирующего фермента и диуретика для лечения нарушений микроциркуляции
ID27544A (id) Agonis dan antagonis muskarinat
DE69917663D1 (de) 2-methyl-thieno-benzodiazepin-formulierung
EE200000146A (et) Monoamiini oksüdaasi inhibiitori kombinatsioon h5-HT 1B antagonisti või osalise agonistiga
FR2607004B1 (fr) Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
ID22060A (id) Senyawa-senyawa 2-imidazolinilaminobenzoksazol berguna sebagai agonis adrenoseptor
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
NO995914L (no) Fremgangsmåte for å påvise risiko for trombose
FR2744621B1 (fr) Determination des tunnels femoral et tibial pour la reconstruction isometrique du ligament croise anterieur
DE29618426U1 (de) Strukturierte Auflagefläche für medizinische Zwecke
BR9714376A (pt) Antagonistas de somatostatina
DK0904070T3 (da) Anvendelse af buckminsterfulleren til behandling af neurotoksiske læsioner
PT920632E (pt) Metodos para deteccao de doencas auto-imunes
NO20005386L (no) Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom
NO20010569D0 (no) Proteaseinhibitorer for anvendelse ved behandling av psoriasis
ES2186782T3 (es) Uso de derivados de tropolona como inhibidores de la enzima inositol-monofosfatasa.